Panmure Gordon Analyst Dr Mike Mitchell said this morning about Allergy Therapeutics (LON:AGY) “This morning Allergy Therapeutics has announced it has completed enrolment with 364 patients in PQBirch204, its phase II randomised, double-blind placebo-controlled dose selection study for Pollinex Quattro Birch. The study is planned to complete by February 2016 with results available in Q2 2016 and should pave the way towards the start of the phase III study in 1Q17. “
Campaign launched to prevent food allergy-related deaths and illness on Teesside
A new campaign has been launched with the aim of preventing food allergy-related illness and deaths across Teesside. Targeted at restaurants and food outlets, all 12 local authorities in the North East have joined forces to